Core Viewpoint - Hualan Co., Ltd. announced a capital increase of RMB 45 million to its wholly-owned subsidiary, Lingqing Intelligent Pharmaceutical Technology Co., Ltd., to enhance its capital strength and support the development of AI-driven pharmaceutical solutions [1] Group 1: Company Overview - Lingqing Intelligent is a key platform for Hualan's business layout in the AI pharmaceutical sector, focusing on innovative drug R&D solutions and services [1] - The subsidiary aims to promote the application of AI technology in drug development and commercialization [1] Group 2: Financial Details - The capital increase will raise Lingqing Intelligent's registered capital from RMB 50 million to RMB 500 million [1] - The funding is intended to strengthen the subsidiary's ability to integrate high-quality industry resources and establish deep collaborations with global upstream and downstream enterprises, technology teams, and research institutions [1]
华兰股份(301093.SZ)：拟4.5亿元对全资子公司灵擎数智增资